TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER (TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER).

How it works

Travasol 2.75% with electrolytes in dextrose 10% is a parenteral nutrition solution. Amino acids provide substrate for protein synthesis, dextrose supplies calories, and electrolytes maintain acid-base balance and osmotic equilibrium.

What the body does with it

Metabolism	Amino acids undergo transamination and deamination in the liver and other tissues; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are regulated by renal and hormonal mechanisms.
Excretion	Renal (primarily as unchanged drug and metabolites). Biliary/fecal excretion is negligible (<5%).
Half-life	Not applicable as a single entity; components have variable half-lives. Dextrose has elimination half-life of ~2-4 hours; amino acids have variable half-lives based on individual metabolic rates.
Protein binding	Minimal to negligible (<5%); dextrose and amino acids are not significantly protein-bound.
Volume of Distribution	Dextrose: ~0.2 L/kg; amino acids: variable, reflects total body water (~0.6 L/kg) but clinical relevance is low due to rapid metabolism.
Bioavailability	Intravenous: 100% (only relevant route). Oral administration is not applicable.
Onset of Action	Intravenous: immediate upon infusion for dextrose (glucose elevation), amino acids for protein synthesis begins within minutes.
Duration of Action	Intravenous: transient effects; dextrose action persists during infusion and for ~1-2 hours post-infusion; amino acids sustain nitrogen balance for hours, requiring continuous infusion.

Classification & Brands

Dosing & administration

Intravenous infusion. Dosage depends on caloric and nitrogen requirements, generally 1-3 L per day in adults providing 4.25 g amino acids and 100 g dextrose per liter.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with severe renal impairment (GFR < 25 mL/min) unless on dialysis. Reduce volume and protein load; monitor electrolytes.
Liver impairment	Use with caution in severe hepatic impairment (Child-Pugh class C). Avoid in hepatic encephalopathy. Modified amino acid formulations may be needed.
Pediatric use	Individualized based on weight (2-3 g amino acids/kg/day) and glucose infusion rate. Typical starting rate 0.5-1 g amino acids/kg/day, titrate upward.
Geriatric use	Monitor renal function and fluid status closely. Start at lower infusion rates. Adjust for comorbidities and polypharmacy.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Excretion into breast milk is minimal; M/P ratio not applicable. Considered safe during lactation when used as directed.
Teratogenic Risk	No teratogenic effects reported in animal studies; dextrose and electrolytes are essential nutrients. Inadequate maternal nutrition may pose fetal risk. Use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

NOT FOR INTRAVENOUS INFUSION; FOR USE ONLY AS A COMPONENT OF PARENTERAL NUTRITION. Deaths have occurred in patients receiving aluminum-containing parenteral nutrition products. Premature neonates are at greater risk. Do not administer intravenously at full strength; must be admixed with other nutrients.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to any component, severe electrolyte imbalances, anuria, severe hepatic disease, and inborn errors of amino acid metabolism.

Clinical Precautions

Precautions

Risk of hyperglycemia, electrolyte imbalances, aluminum toxicity, infection due to central line use, and fluid overload. Monitor serum glucose, electrolytes, and renal function. Use with caution in patients with renal impairment, hepatic disease, or metabolic disorders.

Clinical Tips & Counseling

Drug interactions

Loading safety data…